Abbott Laboratories (ABT)
| Previous Close | 113.86 |
| Open | 114.46 |
| Bid | 116.29 x 800 |
| Ask | 116.32 x 900 |
| Day's Range | 114.32 - 116.65 |
| 52 Week Range | 89.67 - 121.64 |
| Volume | |
| Avg. Volume | 6,195,906 |
| Market Cap | 202.455B |
| Beta (5Y Monthly) | 0.72 |
| PE Ratio (TTM) | 36.71 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.20 (1.93%) |
| Ex-Dividend Date | Jul 15, 2024 |
| 1y Target Est | N/A |
- PR Newswire
Abbott's Lingo™ Continuous Glucose Monitor for Health and Wellness Now Available in the U.S.
Abbott (NYSE: ABT) today announced U.S. availability of Lingo™, the company's first continuous glucose monitoring system available without a prescription. The Lingo system includes a biosensor and a mobile app designed for consumers who want to improve their overall health and wellness. Lingo is based on Abbott's world-leading FreeStyle Libre® continuous glucose monitoring technology1, now used by more than 6 million people with diabetes globally1.
- PR Newswire
Abbott Initiates Clinical Study to Evaluate the Use of Its Deep Brain Stimulation System to Manage Severe Depression
Abbott (NYSE: ABT) announced today it has initiated a pivotal clinical trial, called the TRANSCEND study, to evaluate the use of the company's deep brain stimulation (DBS) system to manage treatment-resistant depression (TRD), a form of major depressive disorder. The U.S. Food and Drug Administration (FDA) granted Abbott Breakthrough Device designation to explore use of DBS for TRD under its Breakthrough Devices Program, which expedites the review of innovative technologies that can improve the
- PR Newswire
Abbott Expands its Pure Bliss™ Line of Infant Formulas to Include European-Made and Organic Products; Offers the First and Only Organic Liquid Formula Available at U.S. Retail Stores
Abbott (NYSE: ABT) today announced the expansion of its Pure Bliss™ by Similac® line of organic, and European-made infant formulas that give parents a variety of products to meet specific formula preferences.
